Notably, several PD-1 inhibitors (Nivolumab, Pembrolizumab, Sintilimab, Camrelizumab, Tislelizumab) and PD-L1 inhibitors (Atezolizumab, Avelumab, Durvalumab) have received approval for cancer therapy and have demonstrated effectiveness in an expanding range of malignancies, including gastroesophageal, melanoma, and lung cancers (4). The gene discussed is CD274; the disease is melanoma.